Regular Member BALDIE42 Posted March 1, 2010 Regular Member Share Posted March 1, 2010 Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment. The breadth of this phase of our trial is tremendous; We have significantly more participants than our Phase 1 study. Atlanta, GA (PRWEB) February 28, 2010 -- Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment. 'The breadth of this phase of our trial is tremendous,' said Kurt Stenn, MD, Vice President and Chief Scientific Officer. 'We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on pattern hair loss.' Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months. The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration. During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth. 'This is leading edge research in our industry,' said Vern Liebmann, Vice President, Operations. 'We've been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we're collectively very excited to see the results beginning later this year.' Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI's cellular regeneration techniques. About Aderans Research Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world's largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration. More information on ARI's study outcomes will be released as studies unfold. To see ARI's latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html Additional information on ARI can be found at www.aderansresearch.com. Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company/ Link to comment Share on other sites More sharing options...
Senior Member why oh why Posted March 2, 2010 Senior Member Share Posted March 2, 2010 great punchline with the 30% the aristocrats!!! my reg is: propecia 1mg EVERYDAY minox 5% twice daily (f the foam) nizoral 1% say la V old buddies .... i'm tryin to keep you Link to comment Share on other sites More sharing options...
Senior Member FinHairLoss Posted March 10, 2010 Senior Member Share Posted March 10, 2010 if it was worthless to continue on do you think they would? Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now